KINASET THERAPEUTICS LTD 13604104 false 2023-10-01 2024-09-30 2024-09-30 The principal activity of the company is drug development. Digita Accounts Production Advanced 6.30.9574.0 true 13604104 2023-10-01 2024-09-30 13604104 2024-09-30 13604104 bus:Micro-entities 2023-10-01 2024-09-30 13604104 bus:AuditExemptWithAccountantsReport 2023-10-01 2024-09-30 13604104 bus:FilletedAccounts 2023-10-01 2024-09-30 13604104 bus:SmallCompaniesRegimeForAccounts 2023-10-01 2024-09-30 13604104 bus:RegisteredOffice 2023-10-01 2024-09-30 13604104 bus:Director1 2023-10-01 2024-09-30 13604104 bus:Director2 2023-10-01 2024-09-30 13604104 bus:EntityHasNeverTraded 2023-10-01 2024-09-30 13604104 bus:PrivateLimitedCompanyLtd 2023-10-01 2024-09-30 13604104 countries:EnglandWales 2023-10-01 2024-09-30 13604104 2022-10-01 2023-09-30 13604104 2023-09-30 iso4217:GBP xbrli:pure

Registration number: 13604104

KINASET THERAPEUTICS LTD

Unaudited Filleted Financial Statements

for the Year Ended 30 September 2024

 

KINASET THERAPEUTICS LTD

Contents

Company Information

1

Balance Sheet

2 to 3

Notes to the Unaudited Financial Statements

2

 

KINASET THERAPEUTICS LTD

Company Information

Directors

R Clarke

F G Morgan

Registered office

71-75 Shelton Street
Covent Garden
London
WC2H 9JQ

Page 1

 

KINASET THERAPEUTICS LTD

(Registration number: 13604104)
Balance Sheet as at 30 September 2024

2024
£

2023
£

Current assets

100

100

Capital and reserves

100

100

1

General information

The company is a private company limited by share capital, incorporated in England and Wales.

The address of its registered office is:
71-75 Shelton Street
Covent Garden
London
WC2H 9JQ
United Kingdom

These financial statements were authorised for issue by the Board on 4 April 2025.

Basis of preparation

The financial statements have been prepared under the historical cost convention and in accordance with FRS 105 'The Financial Reporting Standard applicable to the Micro-entities Regime'.

2

Staff numbers

The average number of persons employed by the company (including directors) during the year, was 2 (2023 - 2). The directors were not remunerated.

For the financial year ending 30 September 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

For the financial year ending 30 September 2024 the company was entitled to exemption from audit under section 480 of the Companies Act 2006 relating to dormant companies.

Directors' responsibilities:

•

The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476; and

•

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared in accordance with the micro-entity provisions of the Companies Act 2006 and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

Page 2

 

KINASET THERAPEUTICS LTD

(Registration number: 13604104)
Balance Sheet as at 30 September 2024

Approved and authorised by the Board on 4 April 2025 and signed on its behalf by:
 

.........................................
F G Morgan
Director

These financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime. As permitted by section 444 (5A) of the Companies Act 2006, the directors have not delivered to the registrar a copy of the Profit and Loss Account.

Page 3